[1] Weissferdt A, Moran CA. Thymic carcinoma, part 1: a clinicopathologic and immunohistochemical study of 65 cases. Am J Clin Pathol 2012; 138: 103–14.
[2] Bryan M. Burt, Xiaopan Yao, Joseph Shrager, Alberto Antonicelli, Sukhmani Padda, Jonathan Reiss, Heather Wakelee, Stacey Su, James Huang, and Walter Scott. Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry. J Thorac Oncol, 2017. 12(1): p. 129-136.
[3] Hosaka Y, Tsuchida M, Toyabe S, Umezu H, Eimoto T, Hayashi J. Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. Ann Thorac Surg, 2010. 89(3): p. 912-7.
[4] Xue L, Wang L, Dong J, Yuan Y, Fan H, Zhang Y, Wang Q, Ding J. Risk factors of myasthenic crisis after thymectomy for thymoma patients with myasthenia gravis. Eur J Cardiothorac Surg, 2017. 52(4): p. 692-697.
[5] Aydiner A, Toker A, Sen F, Bicakci E, Saglam EK, Erus S, Eralp Y, Tas F, Oral EN, Topuz E, Dilege S. Association of clinical and pathological variables with survival in thymoma. Med Oncol, 2012. 29(3): p. 2221-8.
[6] Bae MK, Byun CS, Lee CY, Lee JG, Park IK, Kim DJ, Yang WI, Chung KY. Clinical outcomes and prognosis of recurrent thymoma management. J Thorac Oncol, 2012. 7(8): p. 1304-14.
[7] Zhu L, Zhang J, Marx A, Weiss C, Fang WT. Clinicopathological analysis of 241 thymic epithelial tumors-experience in the Shanghai Chest Hospital from 1997-2004. J Thorac Dis, 2016. 8(4): p. 718-26.
[8] Hosomi Y, Watanabe K, Yamada Y, Horio H, Maeda Y, Okamura T, Hishima T. Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center. BMC Cancer, 2014. 14: p. 349.
[9] Li Q, Su YL, Shen WX. Weixi Shen. A novel prognostic signature of seven genes for the prediction in patients with thymoma. J Cancer Res Clin Oncol. 2019; 145(1): 109–116.
[10] Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643–655.
[11] Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol. 2004;130(4):222–224.
[12] Gümüstas S, Akça A, Inan N, Akgül AG, Liman ST. Characterization of malignant thrombus in an invasive thymoma with intravascular growth. J Radiol Case Rep. 2013;7(2):17–23.
[13] Mimae T, Tsuta K, Kondo T, Nitta H, Grogan TM, Okada M, Asamura H, Tsuda H. Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas. Ann Oncol, 2012. 23(12): p. 3129-37.
[14] Du MJ, Shen Q, Yin H, Rao Q, Zhou MX. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma. Pathol Res Pract, 2016. 212(11): p. 1048-1051.
[15] Fukai I, Masaoka A, Hashimoto T, Yamakawa Y, Mizuno T, Tanamura O. The distribution of epithelial membrane antigen in thymic epithelial neoplasms. Cancer, 1992. 70(8): p. 2077-81.
[16] Omatsu M, Kunimura T, Mikogami T, Hamatani S, Shiokawa A, Masunaga A, Kitami A, Suzuki T, Kadokura M, Morohoshi T. Immunohistochemical analysis of thymic carcinoma focusing on the possibility of molecular targeted and hormonal therapies. Gen Thorac Cardiovasc Surg, 2012. 60(12): p. 803-10.
[17] Hiroshima K, Iyoda A, Toyozaki T, Supriatna Y, Shibuya K, Shimamura F, Haga Y, Yoshida S, Fujisawa T, Ohwada H. Proliferative activity and apoptosis in thymic epithelial neoplasms. Mod Pathol, 2002. 15(12): p. 1326-32.
[18] Ma Y, Li Q, Cui W, Miao N, Liu X, Zhang W, Zhang C, Wang J. Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems. Diagn Pathol, 2012. 7: p. 120.
[19] Chen Y, Zhang Y, Chai X, Gao J, Chen G, Zhang W, Zhang Y. Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors. Biomed Res Int, 2018. 2018: p. 5830547.
[20] Nishi T, Yokoyama S, Takamori S, Matsuo T, Murakami D, Akagi Y, Ohshima K. Thymoma in Patient with Myasthenia Gravis Has Significantly Fewer Forkhead Box P3 Positive Lymphocytes than that without One. Kurume Med J, 2015. 61(3-4): p. 65-71.
[21] Su XY, Wang WY, Li JN, Liao DY, Wu WL, Li GD. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas. Int J Clin Exp Pathol, 2015. 8(5): p. 5354-62.
[22] Badve S, Goswami C, Gökmen-Polar Y, Nelson RP Jr, Henley J, Miller N, Zaheer NA, Sledge GW Jr, Li L, Kesler KA, Loehrer PJ Sr. Molecular analysis of thymoma. PLoS One. 2012;7(8):e42669.
[23] Khoury T, Chandrasekhar R, Wilding G, Tan D, Cheney RT. Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma. Int J Exp Pathol, 2011. 92(2): p. 87-96.
[24] Pan CC, Ho DM, Chen WY, Huang CW, Chiang H. Ki67 labelling index correlates with stage and histology but not significantly with prognosis in thymoma. Histopathology, 1998. 33(5): p. 453-8.
[25] Roden AC, Yi ES, Jenkins SM, Donovan JL, Cassivi SD, Garces YI, Marks RS, Aubry MC. Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomas. Hum Pathol, 2015. 46(1): p. 17-25.
[26] Nonaka D, Henley JD, Chiriboga L, Yee H. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms. Am J Surg Pathol, 2007. 31(7): p. 1038-44.
[27] Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti A, Buttitta F, Felicioni L, Migaldi M, Rea F, Di Chiara F, Mengoli MC, Rossi G. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol, 2012. 23(9): p. 2409-14.
[28] Pan CC, Chen PC, Chou TY, Chiang H. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Hum Pathol, 2003. 34(11): p. 1155-62.
[29] Tateyama H, Sugiura H, Yamatani C, Yano M. Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome. Hum Pathol, 2011. 42(4): p. 533-40.
[30] Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y, Takahashi T, Kondo H, Nakajima T, Yamamoto N. MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. Virchows Arch, 2011. 458(5): p. 615-20.
[31] Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. J Surg Oncol, 2009. 99(7): p. 433-8.
[32] Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho S, Nagai K, Saijo N. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer, 2008. 62(3): p. 316-20.
[33] Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol, 2004. 202(3): p. 375-81.
[34] Thomas A, Chen Y, Berman A, Schrump DS, Giaccone G, Pastan I, Venzon DJ, Liewehr DJ, Steinberg SM, Miettinen M, Hassan R, Rajan A. Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. Lung Cancer, 2016. 101: p. 104-110.